Clinical research has shown that the recurrence of Mantle Cell Lymphoma, a variant of malignant lymphoma, can be reduced by almost 50% in patients who receive maintenance treatment with the antibody rituximab (Rituxan®, Genentech / Biogen Idec). These results were presented by… Continue
Added by Peter Hofland, PhD on June 10, 2011 at 6:00pm —
No Comments